LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Erlotinib | 10 | uM | LJP5 | 3 | M19 | 72 | hr | 1097 | 2437 | 3925 | 0.6208 | 0.5433 |
BT-20 | Gefitinib | 0.04 | uM | LJP6 | 1 | N12 | 72 | hr | 1097 | 3552 | 3610 | 0.9838 | 0.9811 |
BT-20 | Gefitinib | 0.04 | uM | LJP6 | 2 | N12 | 72 | hr | 1097 | 3468 | 3713 | 0.9338 | 0.9237 |
BT-20 | Gefitinib | 0.04 | uM | LJP6 | 3 | N12 | 72 | hr | 1097 | 3549 | 3696 | 0.9601 | 0.9541 |
BT-20 | Gefitinib | 0.12 | uM | LJP6 | 1 | N11 | 72 | hr | 1097 | 3227 | 3610 | 0.8938 | 0.8735 |
BT-20 | Gefitinib | 0.12 | uM | LJP6 | 2 | N11 | 72 | hr | 1097 | 3190 | 3713 | 0.8590 | 0.8344 |
BT-20 | Gefitinib | 0.12 | uM | LJP6 | 3 | N11 | 72 | hr | 1097 | 3174 | 3696 | 0.8587 | 0.8334 |
BT-20 | Gefitinib | 0.37 | uM | LJP6 | 1 | N10 | 72 | hr | 1097 | 3395 | 3610 | 0.9403 | 0.9296 |
BT-20 | Gefitinib | 0.37 | uM | LJP6 | 2 | N10 | 72 | hr | 1097 | 3249 | 3713 | 0.8749 | 0.8536 |
BT-20 | Gefitinib | 0.37 | uM | LJP6 | 3 | N10 | 72 | hr | 1097 | 3249 | 3696 | 0.8790 | 0.8580 |
BT-20 | Gefitinib | 1.11 | uM | LJP6 | 1 | N09 | 72 | hr | 1097 | 2915 | 3610 | 0.8074 | 0.7658 |
BT-20 | Gefitinib | 1.11 | uM | LJP6 | 2 | N09 | 72 | hr | 1097 | 3345 | 3713 | 0.9007 | 0.8846 |
BT-20 | Gefitinib | 1.11 | uM | LJP6 | 3 | N09 | 72 | hr | 1097 | 3167 | 3696 | 0.8568 | 0.8311 |
BT-20 | Gefitinib | 3.33 | uM | LJP6 | 1 | N08 | 72 | hr | 1097 | 3059 | 3610 | 0.8472 | 0.8161 |
BT-20 | Gefitinib | 3.33 | uM | LJP6 | 2 | N08 | 72 | hr | 1097 | 3065 | 3713 | 0.8253 | 0.7932 |
BT-20 | Gefitinib | 3.33 | uM | LJP6 | 3 | N08 | 72 | hr | 1097 | 3278 | 3696 | 0.8868 | 0.8675 |
BT-20 | Gefitinib | 10 | uM | LJP6 | 1 | N07 | 72 | hr | 1097 | 2689 | 3610 | 0.7448 | 0.6848 |
BT-20 | Gefitinib | 10 | uM | LJP6 | 2 | N07 | 72 | hr | 1097 | 2450 | 3713 | 0.6597 | 0.5788 |
BT-20 | Gefitinib | 10 | uM | LJP6 | 3 | N07 | 72 | hr | 1097 | 2782 | 3696 | 0.7526 | 0.7006 |
BT-20 | Nilotinib | 0.04 | uM | LJP5 | 1 | N18 | 72 | hr | 1097 | 4017 | 3735 | 1.0754 | 1.0840 |
BT-20 | Nilotinib | 0.04 | uM | LJP5 | 2 | N18 | 72 | hr | 1097 | 4097 | 3877 | 1.0565 | 1.0613 |
BT-20 | Nilotinib | 0.04 | uM | LJP5 | 3 | N18 | 72 | hr | 1097 | 3777 | 3925 | 0.9622 | 0.9585 |
BT-20 | Nilotinib | 0.12 | uM | LJP5 | 1 | N17 | 72 | hr | 1097 | 3967 | 3735 | 1.0621 | 1.0693 |
BT-20 | Nilotinib | 0.12 | uM | LJP5 | 2 | N17 | 72 | hr | 1097 | 4377 | 3877 | 1.1287 | 1.1375 |
BT-20 | Nilotinib | 0.12 | uM | LJP5 | 3 | N17 | 72 | hr | 1097 | 3664 | 3925 | 0.9334 | 0.9264 |